Participated · Seed · Mar 2026

TippingPoint Biosciences builds a novel drug discovery platform that recreates disease-specific chromatin environments to expose transient protein–protein interfaces within the epigenome that are otherwise inaccessible. The company aims to discover first-in-class, highly selective drugs that target these epigenetic interfaces while sparing healthy cells. TippingPoint’s initial therapeutic focus is on Diffuse Intrinsic Pontine Glioma (DIPG), an aggressive pediatric brainstem tumor driven by chromatin dysfunction. The company was co-founded by Laura Hsieh and chromatin biologist Geeta Narlikar and was spun out of Narlikar’s lab at UCSF. TippingPoint has raised $2.5 million in pre-seed financing including non-dilutive grants and foundation support, received several Golden Ticket awards, and has now closed a $4.5 million seed round to advance its lead program and expand its discovery platform. The platform is described as applicable to multiple disease areas including cancer, neurodegenerative diseases and developmental disorders.

Participated · Seed · Dec 2025

Cellens builds BioFeel, a mechanobiology and machine-learning platform that detects bladder cancer from urine samples by physically “feeling” cellular stiffness with atomic-force microscopy and converting those measurements into biophysical biomarkers. By relying on physics rather than solely on molecular markers, the test addresses tumor heterogeneity that limits current urine assays and eliminates many unnecessary, invasive cystoscopies. In a prospective study of nearly 100 patient samples, BioFeel correctly identified every recurrence case and markedly outperformed FDA-cleared molecular tests that typically reach only 60–65 % sensitivity. The technology originates from research at Tufts University and has been validated with Dartmouth Medical Center and the University of Washington Medical Center. With an estimated 83,190 new U.S. bladder-cancer cases in 2024 and 800,000 patients under surveillance, Cellens targets a large, costly monitoring market. The company plans to use its new capital to advance clinical validation, pursue regulatory clearance and scale commercialization. Cellens has raised $6.5 million in seed funding to date; no revenue metrics have been disclosed.

Participated · Series B · Dec 2025

Paradigm Health provides a unified, AI-powered infrastructure that allows hospitals and biopharmaceutical sponsors to design, recruit for, and execute clinical trials directly within real-world clinical workflows. After acquiring Flatiron Health's Clinical Research Business, the company operates the largest oncology research network in the United States, spanning 45 states, 166 provider organizations, and 2,100 care locations—placing 70% of the U.S. cancer population within reach of a trial site. The network includes 123 community oncology practices and 43 health systems and academic medical centers, 23 of which are NCI-Designated Cancer Centers. Paradigm's software automates patient matching and site feasibility, enabling health systems to enroll patients four times faster while reducing costs and administrative burden for sponsors. The company currently supports Phase I–III oncology studies for 15 of the top 20 global pharmaceutical companies and is expanding into neuroscience, cardiovascular, metabolic, and other high-need therapeutic areas. It has also launched a Trial Design Service to help sponsors create interventional and pragmatic studies embedded in routine care. The newly raised capital will accelerate platform development and expand its commercial footprint in the U.S. and internationally.

Participated · Equity · Jun 2025

Signify Bio is a Dallas, TX–based biotechnology company focused on improving development of in situ protein therapeutics by harnessing the human body’s natural protein-production capabilities. It combines signal peptide‑engineered control with mRNA‑encoded design to enable precise and rapid development of personalized medicines. The company’s SEND platform and iPhos lipid nanoparticles are designed to enable targeted, localized delivery of therapeutic proteins across multiple disease areas. Signify positions its approach to address unmet needs by delivering protein therapeutics directly where needed. Its management team includes co‑founders and senior scientists from UT Southwestern and industry veterans from Pfizer, Intellia and other organizations. The company intends to use the funds from the financing to expand operations and accelerate R&D efforts.

Participated · Series C · May 2025

CellCentric is a privately held, clinical-stage biotech company developing inobrodib, an orally bioavailable p300/CBP inhibitor. The lead program is in registration-enabling clinical trials for patients with relapsed/refractory multiple myeloma, and the company is enrolling a Phase 2 DOMMINO-1 study in the UK and US. CellCentric plans to initiate the global Phase 3 DOMMINO-2 trial in the second half of 2026. The company holds an IP portfolio and has clinical collaborations and strategic partnerships that provide external validation. Led by CEO Will West, CellCentric is based in Cambridge, UK, and maintains an additional office in Boston, MA. The article did not disclose revenue or other operating metrics.